Delivery Order SPE2DB22D3016-SPE2DB25FBGB8
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $31,987.71 to AmerisourceBergen Drug Corp for the supply of Tagrisso 80 mg tablets (30-count units) on August 27, 2025, with an ultimate completion date of September 18, 2025. This competitive award, with no set-aside designation, reflects firm fixed-price pricing terms and represents a pharmaceutical supply delivery to support federal medical procurement needs. The place of performance is AmerisourceBergen's corporate office...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Tagrisso 80 mg tablets in a quantity of 30 units. This Firm Fixed Price delivery order carries a ceiling value of $10,662.57 and is scheduled for completion by August 18, 2025. The contract was competitively awarded with no set-aside designation and will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. This delivery order operates...
- The Defense Logistics Agency awarded a delivery order valued at $21,325.14 to AmerisourceBergen Drug Corp for the supply of Tagrisso 80 mg tablets (30-count) with a completion date of September 11, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside contract and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor,...
- The Defense Logistics Agency awarded a delivery order valued at $21,325.14 to AmerisourceBergen Drug Corp for the supply of Tagrisso 80 mg tablets (30-count units) on August 25, 2025, with completion scheduled for September 16, 2025. This competitive award, issued under firm fixed pricing with no set-aside designation, supports federal medical procurement needs through AmerisourceBergen's extensive pharmaceutical distribution network. The contractor will perform this delivery order from its...
- The Defense Logistics Agency awarded a delivery order valued at $10,662.57 to AmerisourceBergen Drug Corp for the supply of Tagrisso 80 mg tablets (30-count packages). This competitive award, issued on August 12, 2025, with an ultimate completion date of September 3, 2025, represents a firm fixed-price delivery order with no set-aside designation. Performance of this contract will take place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Tagrisso is a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Tagrisso 80 mg tablets (30-count units) with a ceiling value of $31,987.71. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 18, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award carries no set-aside designation, indicating that AmerisourceBergen Drug Corp...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Tagrisso 80 mg tablets (30-count units) valued at $10,662.57. This firm fixed price delivery order, with an ultimate completion date of September 9, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The award was competitively procured with no set-aside designation. AmerisourceBergen,...
- The Defense Logistics Agency awarded a delivery order valued at $31,987.71 to AmerisourceBergen Drug Corp for the supply of Tagrisso 80 mg tablets (30-count units) on July 23, 2025, with an ultimate completion date of August 13, 2025. This firm fixed-price delivery order was awarded without a set-aside designation through open competition, reflecting the contractor's capability to meet federal procurement standards. The contract will be performed at AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded a delivery order valued at approximately $32,000 to AmerisourceBergen Drug Corp for the supply of Tagrisso 80 mg tablets (30-count units) on July 25, 2025, with an ultimate completion date of August 15, 2025. The contract utilizes firm fixed pricing with no set-aside designation, indicating competitive award. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical federal vendor specializing in...
- The Defense Logistics Agency (DLA) awarded a $21,325.14 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Tagrisso 80 mg tablets (30-count units) with an ultimate completion date of August 14, 2025. This non-set-aside contract was competitively awarded on July 24, 2025, with performance occurring at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions...
- SPE2DB22D3016Indefinite Delivery Contract
- SPE2DB22D3016-SPE2DB25FBGB8Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $53,217.88 to AmerisourceBergen Drug Corp for the supply of Tagrisso 80 mg tablets (30-count units) on August 25, 2025, with an ultimate completion date of September 16, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical federal medical procurement vendor that serves military and veteran healthcare systems through the DLA's Medical Supply Chain. This delivery order is issued under AmerisourceBergen Drug Corp's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. The parent IDC functions as a comprehensive global pharmaceutical support vehicle enabling the contractor to supply a wide range of pharmaceutical products and medical supplies supporting military healthcare programs worldwide. The contract structure reflects DLA's strategy to maintain flexible pharmaceutical procurement capabilities across multiple therapeutic domains, with the agency planning to establish additional regional Pharmaceutical Prime Vendor Global Program Generation V contracts involving multiple award recipients.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $53.2k | 8/25/25 |